KASUS RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA-MITIS YANG TERDIAGNOSIS PADA SAAT LANJUT USIA
DOI:
https://doi.org/10.33820/mdvi.v50i1.402Keywords:
lanjut usia, mitis, recessive dystrophic epidermolysis bullosaAbstract
Introduction: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare bullous disease caused by mutations in the COL7A1 gene encoding anchoring fibril collagen that maintains skin integrity. Case: Male, 67-year-old, presented with blisters and wound on various parts of the body, worsening in the recent year. They had been known to easily appear after trauma since. Vesicles-bullae, erosions-excoriations, milia, and atrophic scars were found on the axillae, groins, and limbs, as well as hyperkeratosis and anonychia of the hands and. Histopathological examination showed subepidermal cleft, milia and fibrosis, without immunoglobulin deposits on immunofluorescence. Discussion: Contrary to classical RDEB, blisters in mitis variant do not always cause impairment. The pronounced symptoms in advanced age might be mistaken for epidermolysis bullosa acquisita. Negative immunoglobulin deposition is the diagnostic key, confirming that blister does not result from an autoimmune process, but rather, from trauma to the abnormal skin, more so by flattening of the rete ridges in the elderly. In the absence of definitive therapy, treatment is symptomatic. Conclusion: The diagnosis RDEB-mitis might be missed in geriatric. Correct diagnosis has implication on management because not only does RDEB-mitis require no immunosuppressant, measures to minimize blister formation is more important to save patient from complication.
Downloads
References
2. Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, dkk. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614–27.
3. Marinkovich MP. Inherited epidermolysis bullosa. Dalam: Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, dkk., penyunting. Fitzpatrick’s dermatology. Edisi ke-9. New York: McGraw-Hill; 2019. h. 1011–30.
4. Kridin K, Kneiber D, Kowalski EH, Valdebran M, Amber KT. Epidermolysis bullosa acquisita: A comprehensive review. Autoimmun Rev. 2019;18(8):786–95.
5. Hignett E, Sami N. Pediatric epidermolysis bullosa acquisita: A review. Pediatr Dermatol. 2021;38(5):1047–50.
6. Woodley DT, Chen M. Epidermolysis bullosa acquisita. Dalam: Kang S, Amagai M, Bruckner A, Enk A, Margolis D, McMichael A, dkk., penyunting. Fitzpatrick’s dermatology. Edisi ke-9. New York: McGraw-Hill; 2019. h. 927–79.
7. Rigoni Gürtler TG, Diniz LM, De Souza Filho JB. Recessive dystrophic epidermolysis bullosa mitis - Case report. An Bras Dermatol. 2005;80(5):503–8.
8. Soro L, Bartus C, Purcell S. Recessive dystrophic epidermolysis bullosa: A review of disease pathogenesis and update on future therapies. J Clin Aesthet Dermatol. 2015;8(5):41–6.
9. Rashidghamat E, McGrath JA. Novel and emerging therapies in the treatment of recessive dystrophic epidermolysis bullosa. Intractable Rare Dis Res. 2017;6(1):6–20.
10. Tang JY, Marinkovich MP, Lucas E, Gorell E, Chiou A, Lu Y, dkk. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2021;16(1).
11. Kim M, Li M, Intong-Wheeler LRA, Tran K, Marucci D, Murrell DF. Epidemiology and outcome of squamous cell carcinoma in epidermolysis bullosa in Australia and New Zealand. Acta Derm Venereol. 2018;98(1):70–6.
